PHTHALATES FACTS PHTHALATES ARE KNOWN TO BREAK DOWN IN THE HUMAN BODY Research has shown that after entering the body, phthalate are broken down into metabolites within minutes and pass out quickly in urine.2 PHTHALATE EXPOSURE IS CONSIDERED LOW Despite the fact that phthalates are used in a wide range of products, human exposure from all sources is considered to be extremely low.2 PHTHALATES ARE A USEFUL CHOICE FOR HEALTHCARE Flexible vinyl tubing does not react with most medications, allowing for reliable administration of drugs, while flexible vinyl bags prevent blood contamination and extend shelf life of the blood.3 PHTHALATES ARE REGULATED Based on earlier studies, a few specific phthalates have been banned for use in toys or other items for sale to children under twelve to reduce risk of overexposure through hand-to- mouth behaviors. 1 Source: chemicalsafetyfacts.org 2 Source: Centers for Disease Control and Prevention 3 Source: thisisplastics.com www.avient.com Copyright © 2020, Avient Corporation. Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications.

Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. Contact your sales representative for more information, or to learn more about custom solutions for your application.

Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

OnCap™ Anti-fog Additives Fog formation on food packaging frustrates consumers, can lead to product spoilage, and ultimately hinders sales. Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications.

KEY CHARACTERISTICS • Excellent lot-to-lot and within-lot consistency for high-quality homogeneous black shades • Easy processing and support of a long-lasting spin pack lifetime • Fastness properties and specification tolerances on par with high-end products on the market • Standard and bluish undertones available in high pigment loadings for an efficient and competitive coloration package • Can be combined with additives into a single combination concentrate for convenience • Compliance with global, regional, and local standards and regulations* RECOMMENDED USE • In most cases, the concentrate is added directly to the resin using gravimetric or volumetric dosing units; for some processes, the concentrate can be added via a side stream extruder (direct spinning) • The recommended dosages are from 3% for the typical automotive, technical, and carpet applications and up to 6% for apparel, footwear, and home textile yarns * Contact your local sales representative for more information on regulatory compliance PRODUCT BULLETIN Copyright © 2022, Avient Corporation. Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications.

Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. Contact your Avient sales representative for product guidance from our experts.

Product Family and Temperatures Product Family Mold Melt Nozzle Zone 3 Zone 2 Zone 1 Feed SBS Formulations 75-90ºF (25-32ºC) 370-390ºF 200ºC) 370-390ºF 200ºC) 360-380ºF (185- 195ºC) 340-360ºF 182ºC) 300-330ºF (150- 165ºC) 100-150ºF (40-65ºC) SEBS Formulations 110-130ºF (43-55ºC) 370-430ºF 220ºC) 390-430ºF (200- 220ºC) 390-430ºF (200- 220ºC) 370-390ºF 200ºC) 350-370ºF (175- 190ºC) 100-170ºF (40-75ºC) Supersoft Formulations 110-130ºF (43-55ºC) 340-390ºF 200ºC) 360-390ºF (180- 200ºC) 360-390ºF (180- 200ºC) 335-375ºF 190ºC) 300-330ºF (150- 165ºC) 100-120ºF (40-50ºC) Setting Shot Size When starting up a new mold, begin with short-shots, then gradually increase the shot size until all part cavities are 80-90% filled.

They use words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance and/or sales Adjusted EPS is calculated as follows: Adjusted EPS 2006Y* 2007Y* 2008Y* 2009Y* 2010Y 2011Y 2012Y 2013Y 2014Y 2015Y Net income (loss) attributable to PolyOne common shareholders $ 130.9 $ 40.9 $ (417.0) $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 Joint venture equity earnings, after tax (68.5) (26.1) (20.8) (19.0) (14.7) (3.7) - - - - Special items, after tax(1) (51.2) 10.7 457.2 (75.9) (72.5) (72.8) 36.2 32.6 90.5 28.9 Adjusted net income $ 11.2 $ 25.5 $ 19.4 $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 Diluted shares 92.8 93.1 92.7 93.4 96.0 94.3 89.8 96.5 93.5 88.7 Adjusted EPS $ 0.12 $ 0.27 $ 0.21 $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 Adjusted EPS Q1 2009* Q2 2009* Q3 2009* Q4 2009* Q1 2010 Q2 2010 Q3 2010 Q4 2010 Net income attributable to PolyOne common shareholders $ 3.3 $ 1.3 $ 51.3 $ 50.8 $ 20.1 $ 44.7 $ 0.1 $ 87.6 Joint venture equity earnings, after tax (8.2) (5.8) (3.0) (2.0) (0.5) (4.5) (6.2) (3.5) Special items, after tax(1) (10.2) 9.2 (36.9) (38.0) (3.8) (22.1) 25.4 (72.0) Adjusted net (loss) income $ (15.1) $ 4.7 $ 11.4 $ 10.8 $ 15.8 $ 18.1 $ 19.3 $ 12.1 Diluted shares 92.2 93.5 93.9 94.4 95.3 96.3 96.3 97.4 Adjusted EPS $ (0.16) $ 0.05 $ 0.12 $ 0.11 $ 0.17 $ 0.19 $ 0.20 $ 0.12 Adjusted EPS Q1 2011 Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Net income attributable to PolyOne common shareholders $ 106.0 $ 23.1 $ 16.0 $ 8.3 $ 15.3 $ 18.4 $ 19.4 $ 0.2 Joint venture equity earnings, after tax (3.7) - - - - - - - Special items, after tax(1) (81.3) 1.3 2.8 4.4 6.2 8.9 5.4 15.7 Adjusted net income $ 21.0 $ 24.4 $ 18.8 $ 12.7 $ 21.5 $ 27.3 $ 24.8 $ 15.9 Diluted shares 96.4 95.5 94.0 91.9 90.7 90.7 90.2 90.5 Adjusted EPS $ 0.22 $ 0.26 $ 0.20 $ 0.14 $ 0.24 $ 0.30 $ 0.28 $ 0.18 2 Adjusted EPS Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Net income (loss) attributable to PolyOne common shareholders $ 11.2 $ 38.6 $ 23.2 $ 21.0 $ 29.4 $ 30.9 $ 32.3 $ (14.6) Special items, after tax(1) 17.7 (2.0) 12.3 4.6 12.5 17.4 13.1 47.5 Adjusted net income $ 28.9 $ 36.6 $ 35.5 $ 25.6 $ 41.9 $ 48.3 $ 45.4 $ 32.9 Diluted shares 92.8 99.1 98.1 97.2 95.7 94.3 93.1 91.3 Adjusted EPS $ 0.31 $ 0.37 $ 0.36 $ 0.26 $ 0.44 $ 0.51 $ 0.49 $ 0.36 Adjusted EPS Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Net income attributable to PolyOne common shareholders $ 30.2 $ 66.8 $ 44.5 $ 3.1 $ 39.1 Special items, after tax(1) 11.4 (15.9) 3.0 30.4 9.1 Adjusted net income $ 41.6 $ 50.9 $ 47.5 $ 33.5 $ 48.2 Diluted shares 90.1 89.8 88.4 86.6 85.5 Adjusted EPS $ 0.46 $ 0.57 $ 0.54 $ 0.39 $ 0.56 Adjusted operating margin is calculated as follows: Adjusted operating margin Q1 2009* Q2 2009* Q3 2009* Q4 2009* YTD 2009* Q1 2010 Q2 2010 Q3 2010 Q4 2010 YTD 2010 Operating Income $ 9.9 $ 17.1 $ 57.9 $ 52.2 $ 137.1 $ 32.3 $ 58.6 $ 42.0 $ 26.3 $ 159.2 Special items (1) (1.3) 4.6 (27.5) (24.5) (48.7) - (14.5) 5.5 4.2 (4.8) Joint venture equity earnings (12.8) (9.0) (4.8) (3.1) (29.7) (0.8) (7.1) (9.7) (5.5) (23.1) Adjusted operating (loss) income $ (4.2) $ 12.7 $ 25.6 $ 24.6 $ 58.7 $ 31.5 $ 37.0 $ 37.8 $ 25.0 $ 131.3 Sales $ 463.4 $ 496.5 $ 548.3 $ 552.5 $ 2,060.7 $ 604.0 $ 666.2 $ 650.7 $ 585.3 $ 2,506.2 Operating Margin (0.9)% 2.6% 4.7% 4.5% 2.8% 5.2% 5.6% 5.8% 4.3% 5.2% Adjusted operating margin Q1 2011 Q2 2011 Q3 2011 Q4 2011 YTD 2011 Q1 2012 Q2 2012 Q3 2012 Q4 2012 YTD 2012 Operating income (loss) $ 173.4 $ 42.4 $ 33.4 $ (46.2) $ 203.0 $ 37.4 $ 43.3 $ 43.5 $ 13.3 $ 137.5 Special items (1) (127.2) 2.7 4.9 72.9 (46.7) 8.5 11.8 8.3 25.3 53.9 Joint venture equity earnings (5.7) - - - (5.7) - - - - - Adjusted operating income $ 40.5 $ 45.1 $ 38.3 $ 26.7 $ 150.6 $ 45.9 $ 55.1 $ 51.8 $ 38.6 $ 191.4 Sales $ 682.8 $ 723.4 $ 694.0 $ 609.2 $ 2,709.4 $ 745.5 $ 756.6 $ 707.7 $ 651.0 $ 2,860.8 Operating Margin 5.9% 6.2% 5.5% 4.4% 5.6% 6.2% 7.3% 7.3% 5.9% 6.7% 3 Adjusted operating margin Q1 2013 Q2 2013 Q3 2013 Q4 2013 YTD 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 YTD 2014 Operating income (loss) $ 40.5 $ 80.7 $ 61.6 $ 48.7 $ 231.5 $ 56.4 $ 49.4 $ 63.6 $ (14.3) $ 155.1 Special items (1) 16.6 (5.2) 10.8 7.8 30.0 22.9 39.8 22.0 80.2 164.9 Adjusted operating income $ 57.1 $ 75.5 $ 72.4 $ 56.5 $ 261.5 $ 79.3 $ 89.2 $ 85.6 $ 65.9 $ 320.0 Sales $ 801.1 $ 1,037.6 $ 1,008.9 $ 923.6 $ 3,771.2 $ 1,002.3 $ 1,005.5 $ 958.4 $ 869.3 $ 3,835.5 Operating Margin 7.1% 7.3% 7.2% 6.1% 6.9% 7.9% 8.9% 8.9% 7.6% 8.3% Adjusted operating margin Q1 2015 Q2 2015 Q3 2015 Q4 2015 YTD 2015 Q1 2016 Operating income $ 70.1 $ 80.3 $ 69.2 $ 31.3 $ 250.9 $ 71.3 Special items (1) 9.3 11.9 18.7 31.4 71.3 13.8 Adjusted operating income $ 79.4 $ 92.2 $ 87.9 $ 62.7 $ 322.2 $ 85.1 Sales $ 873.1 $ 887.1 $ 841.6 $ 775.8 $ 3,377.6 $ 847.0 Operating Margin 9.1% 10.4% 10.4% 8.1% 9.5% 10.0% Adjusted gross margin is calculated as follows: (In millions) Twelve Months Ended December 31, 2015 Gross margin - GAAP $ 681.5 Special items in gross margin(1) 39.7 Gross margin before special items $ 721.2 Specialty operating income mix percentage is calculated as follows: Platform operating income mix percentage 2005* 2010* 2015 Color, Additives and Inks $ 4.3 $ 37.7 $ 135.4 Specialty Engineered Materials 0.4 49.7 79.6 Designed Structures and Solutions - - 13.8 Specialty Platform $ 4.7 $ 87.4 $ 228.8 Performance Products and Solutions 75.7 54.0 57.4 Distribution 19.5 42.0 68.0 Joint ventures 91.9 18.9 — Corporate and eliminations (51.5) (27.7) (103.3) Operating income GAAP $ 140.3 $ 174.6 $ 250.9 Less: Corporate operating expense 51.5 27.7 103.3 Operating income excluding Corporate $ 191.8 $ 202.3 $ 354.2 Specialty platform operating mix percentage 2% 43% 65% 4 Adjusted EBITDA and net debt to adjusted EBITDA is calculated as follows: (In millions) Q2 2015 Q3 2015 Q4 2015 Q1 2016 Trailing Twelve Months Ended March 31, 2016 Income (loss) from continuing operations, before income taxes $ 63.4 $ 51.4 $ (0.4) $ 57.0 $ 171.4 Interest expense, net 16.2 16.2 15.6 14.6 62.6 Depreciation and amortization 25.0 28.3 25.9 27.2 106.4 Special items, impact on income (loss) from continuing operations before income taxes(1) 11.9 18.6 47.8 13.6 91.9 Accelerated depreciation included in special items (0.2) (4.3) (1.6) (2.8) (8.9) Adjusted EBITDA $ 116.3 $ 110.2 $ 87.3 $ 109.6 $ 423.4 Short-term and current portion of long-term debt $ 18.6 Long-term debt 1,174.3 Less: Cash and cash equivalents (155.4) Net Debt 1,037.5 Net Debt/TTM Adjusted EBITDA 2.5 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principal, discontinued operations or the related resegmentation Special items include charges related to specific strategic initiatives or financial restructuring such as: consolidation of operations; debt extinguishment costs; costs incurred directly in relation to acquisitions or divestitures; employee separation costs resulting from personnel reduction programs, plant phase-in costs, executive separation agreements; asset impairments; mark-to-market adjustments associated with actuarial gains and losses on pension and other post-retirement benefit plans; environmental remediation costs, fines, penalties and related insurance recoveries related to facilities no longer owned or closed in prior years; gains and losses on the divestiture of operating businesses, joint ventures and equity investments; gains and losses on facility or property sales or disposals; results of litigation, fines or penalties, where such litigation (or action relating to the fines or penalties) arose prior to the commencement of the performance period; one-time, non-recurring items; the effect of changes in accounting principles or other such laws or provisions affecting reported results; and tax adjustments.